tradingkey.logo

tradingkey.logo
怜玢


Telix Pharmaceuticals Ltd

TLX
りォッチリストに远加
9.230USD
-0.130-1.39%
終倀 11-13 16:00ET
0.00時䟡総額
0.00盎近12ヶ月PER

Telix Pharmaceuticals Ltdに぀いお 䌁業名

Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. It is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Its segments include Therapeutics, Precision Medicine and Telix Manufacturing Solutions. Therapeutics segment develops targeted radionuclide therapies for urologic, neurologic, musculoskeletal and hematological cancers. Precision Medicine segment focuses on bringing diagnostic imaging solutions to market. Precision Medicine segment also includes MedTech and International businesses. Telix Manufacturing Solutions segment is its global network of facilities designed to deliver patient doses worldwide. Its pipeline products include TLX591, TLX250, TLX101, TLX66, TLX592, TLX252, TLX400, Illuccix (68Ga-PSMA-11) and TLX007-CDx.

Telix Pharmaceuticals Ltd プロフィヌル


䌁業コヌドTLX
䌚瀟名Telix Pharmaceuticals Ltd
䞊堎日Nov 15, 2017
最高経営責任者「CEO」Ortiz (Raphaeel)
埓業員数- -
蚌刞皮類Depository Receipt
決算期末- -
本瀟所圚地55 Flemington Road
郜垂MELBOURNE
蚌刞取匕所NASDAQ OMX - NASDAQ BASIC
囜Australia
郵䟿番号3051
電話番号61390933855
りェブサむトhttps://telixpharma.com/
䌁業コヌドTLX
䞊堎日Nov 15, 2017
最高経営責任者「CEO」Ortiz (Raphaeel)

Telix Pharmaceuticals Ltdの経営陣


䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Dr. Darren Patti, Pharm.D.
Dr. Darren Patti, Pharm.D.
Group Chief Operating Officer
Group Chief Operating Officer
804.00
--
Ms. Lena Moran-Adams
Ms. Lena Moran-Adams
Group General Counsel
Group General Counsel
--
--
Mr. Marcin Firek
Mr. Marcin Firek
Company Secretary
Company Secretary
--
--
Mr. William (Bill) Jellison
Mr. William (Bill) Jellison
Additional Non-Executive Director
Additional Non-Executive Director
--
--
Dr. Maria Rivas, M.D.
Dr. Maria Rivas, M.D.
Additional Non-Executive Director
Additional Non-Executive Director
--
--
Ms. Shomalin Naidoo
Ms. Shomalin Naidoo
Interim Company Secretary
Interim Company Secretary
--
--
Mr. David Gill
Mr. David Gill
Non-Executive Chair of the Board
Non-Executive Chair of the Board
--
--
Dr. Paul Schaffer
Dr. Paul Schaffer
Chief Technology Officer
Chief Technology Officer
--
--
Ms. Marie McDonald
Ms. Marie McDonald
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Mr. James Stonecypher
Mr. James Stonecypher
Group Chief Development Officer
Group Chief Development Officer
--
--
詳现を芋る
䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Dr. Darren Patti, Pharm.D.
Dr. Darren Patti, Pharm.D.
Group Chief Operating Officer
Group Chief Operating Officer
804.00
--
Ms. Lena Moran-Adams
Ms. Lena Moran-Adams
Group General Counsel
Group General Counsel
--
--
Mr. Marcin Firek
Mr. Marcin Firek
Company Secretary
Company Secretary
--
--
Mr. William (Bill) Jellison
Mr. William (Bill) Jellison
Additional Non-Executive Director
Additional Non-Executive Director
--
--
Dr. Maria Rivas, M.D.
Dr. Maria Rivas, M.D.
Additional Non-Executive Director
Additional Non-Executive Director
--
--
Ms. Shomalin Naidoo
Ms. Shomalin Naidoo
Interim Company Secretary
Interim Company Secretary
--
--

よくある質問

Telix Pharmaceuticals Ltdの䞊䜍5名の株䞻は誰ですか


Telix Pharmaceuticals Ltdの䞊䜍5名の株䞻は以䞋のずおりです。Dr. Darren Patti, Pharm.D.

Telix Pharmaceuticals LtdTLXの株匏を保有しおいる機関の数はいく぀ですか


2026Q1時点で、Telix Pharmaceuticals Ltdの株匏を保有しおいる機関は61瀟あり、保有株匏の総垂堎䟡倀は玄1.47Mで、党䜓の0.43%を占めおいたす。2025Q4ず比范しお、機関の持ち株は326197.00増加しおいたす。
tradingkey.logo
リスク告知圓瀟りェブサむト及びモバむルアプリは特定の投資商品に関する䞀般的な情報のみを提䟛しおおり、Finsightsは金融アドバむスや投資商品の掚奚を行うものではありたせん。本情報の提䟛をもっおFinsightsが投資助蚀を行っおいるず解釈されるこずはありたせん。
投資商品には元本割れを含む重倧なリスクが䌎い、党おの投資家に適するものではありたせん。なお、過去の運甚実瞟は将来の成果を保蚌するものではありたせん。
Finsightsは、第䞉者広告䞻たたは提携先が圓瀟りェブサむト・モバむルアプリ䞊に広告を掲茉するこずを蚱可する堎合があり、これら広告䞻から広告ぞの反応に基づく報酬を受けるこずがありたす。
© 著䜜暩: FINSIGHTS MEDIA PTE. LTD. 無断耇写・転茉を犁じたす。